China's medical products administrator approved Hutchmed's (HKG:0013) supplemental new drug application for its savolitinib drug for a type of locally advanced or metastatic non-small cell lung cancer, according to a Tuesday filing with the Hong Kong Exchange.
The drug, branded Orpathys, is indicated for non-small cell lung cancer with MET exon 14 skipping alteration mutation, which is seen in patients over 70 years old.
China also converted the conditional approval for Orpathys into a full one, the filing said.
Shares closed 3% higher in Hong Kong during Tuesday's trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。